The purpose of the proposal is to characterize further cell interactions with fibrinogen and fibrin. We will identify and characterize the fibrinogen binding sites on the glycoprotein IIb/IIIa complex. We have observed that limited proteolysis of platelet membranes results in the exposure of fibrinogen receptors and in the release of a GP IIIa-derived, 80kDa component and a 66kDa component which appear to represent the C-terminal portion of the molecule. This suggests that fibrinogen binding sites are located in the NH2-terminal portion of the GPIIIa molecule. The GPIIIa and 80kDa components bind to insolubilized anti-GPIIb/IIIa monoclonal antibody, which blocks fibrinogen binding to platelets, whereas the 66kDa component does not interact with this antibody. We propose to isolate the fragment of GPIIIa associated with the fibrinogen binding domain and to study its effect on platelet- fibrinogen interaction. We also propose to test the hypothesis that limited proteolysis of the NH2-terminal domain of GPIIIa, or its reduction, may change the conformation of this molecule and lead to the exposure of fibrogen receptors. Furthermore we intend to produce recombinant DNA trigramin; trigramin is a low molecular weight peptide (72 amino acids) purified to homogeneity in our laboratory from T. gramineusu snake venom. It inhibits specifically the binding of 125I-fibrinogen to the GPIIb/IIIa complex with a Ki of 10-8 M. Trigramin contains the RGD (arg-gly- ser) sequence but its biological activity depends on secondary and tertiary structure. lt is also 500 times more active than RGDS. We propose, by isolating active peptide fragments of trigramin and by site directed mutagenesis, to study the relationship between the structure and function of this molecule. We further propose: to use trigramin to investigate platelet-fibrinogen interactions; to study the effect of trigramin on the adhesion of platelets and cultured cells to sutstrata cultured with adhesive proteins; and to explore the potential application of trigramin in the prevention of the formation of platelet thromboemboli in vivo. Finally, we ill compare the interaction of fibrinogen and of polymerizing fibrin with platelets. We propose to test the hypothesis that polymerizing fibrin monomers bind to platelet surface receptors other than those associated with the GPIlb/IIIa complex.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL015226-16
Application #
3334886
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1988-07-01
Project End
1993-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
16
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Temple University
Department
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Wierzbicka, I; Kowalska, M A; Lasz, E C et al. (1997) Interaction of beta 3 integrin-derived peptides 214-218 and 217-231 with alpha IIb beta 3 complex and with fibrinogen A alpha-chain. Thromb Res 85:115-26
McLane, M A; Kowalska, M A; Silver, L et al. (1994) Interaction of disintegrins with the alpha IIb beta 3 receptor on resting and activated human platelets. Biochem J 301 ( Pt 2):429-36
Kowalska, M A; Juliano, D; Trybulec, M et al. (1994) Zinc ions potentiate adenosine diphosphate-induced platelet aggregation by activation of protein kinase C. J Lab Clin Med 123:102-9
Trybulec, M; Kowalska, M A; McLane, M A et al. (1993) Exposure of platelet fibrinogen receptors by zinc ions: role of protein kinase C. Proc Soc Exp Biol Med 203:108-16
Beviglia, L; Poggi, A; Rossi, C et al. (1993) Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins. Thromb Res 71:301-15
Lasz, E C; McLane, M A; Trybulec, M et al. (1993) Beta 3 integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: significance of RGD sequences and fibrinogen A alpha-chain. Biochem Biophys Res Commun 190:118-24
Cook, J J; Trybulec, M; Lasz, E C et al. (1992) Binding of glycoprotein IIIa-derived peptide 217-231 to fibrinogen and von Willebrand factors and its inhibition by platelet glycoprotein IIb/IIIa complex. Biochim Biophys Acta 1119:312-21
Shigeta, O; Gluszko, P; Downing, S W et al. (1992) Protection of platelets during long-term extracorporeal membrane oxygenation in sheep with a single dose of a disintegrin. Circulation 86:II398-404
Fishman, S J; Wylonis, L J; Glickman, J D et al. (1991) Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. J Surg Res 51:93-8
Calvete, J J; Schafer, W; Soszka, T et al. (1991) Identification of the disulfide bond pattern in albolabrin, an RGD-containing peptide from the venom of Trimeresurus albolabris: significance for the expression of platelet aggregation inhibitory activity. Biochemistry 30:5225-9

Showing the most recent 10 out of 45 publications